The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.

A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in ...

Calley Means, a MAHA leader who just resigned from the Trump administration, says Americans "are being duped and gaslighted ...

The Trump administration is facing another lawsuit over its sweeping changes to Medicaid less than a week after a federal ...

Katherine MacPhail is a reporter and editorial events programmer for STAT. CHICAGO — What if the key to getting cancer immunotherapy to parts of the world that can’t access it is lowering the dose? A ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Isabella is a chronic disease reporter writing about how the Trump administration is tackling the nation’s health epidemic — or not. You can reach her on Signal at isabellacueto.03. WASHINGTON — ...

Two newly elected lawmakers with science backgrounds hope to push back against Trump administration cuts to health equity programs.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

Voters in 2026 midterm elections decided state health policy ballot measures on abortion rights, marijuana laws, science ...